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RESEARCH LETTERS

LESS IS MORE
Cervical Cancer Screening Intervals, 2006 to 2009: Moving Beyond Annual Testing
C linical guidelines recommend that women 30 years and older with a negative test result for oncogenic human papillomavirus (HPV) and with a concurrent normal Papanicolaou test result (cotesting) not be tested again for at least 3 years. 1 Previous studies, however, indicate that primary care providers continue to perform annual testing regardless of prior test results. 2, 3 Our objective was to examine clinicians' reported behaviors regarding cervical cancer screening intervals over a 4-year period after the endorsement of cotesting. Table 2 ).
Methods
The analysis included 2087 primary care providers after excluding practitioners who were not aware of the HPV DNA test in their practice, unknown, or missing (n = 84). Potential differences in guideline-consistent recommendations between years were compared with t test statistic. Data were analyzed with SUDAAN 10.1 (RTI International) to account for the sampling design and nonresponse.
Results. During the study period, 26% of NAMCS and NHAMCS providers were obstetrician-gynecologists and the remainder practiced general medicine. Nearly 60% of NAMCS providers were male, 64% were 45 years and older, 84% worked in metropolitan areas, and 69% worked in practices with fewer than 6 practitioners. Guideline adherence was low overall, especially in vignettes portraying women with normal test results (vignettes 1, 2, and 3). After normal co-testing results (vignettes 2 and 3), most respondents (67.1% to 93.8%) recommended Papanicolaou tests sooner than recommended by guidelines. Adherence was particularly low for a woman without prior Papanicolaou tests and normal co-testing results (vignette 3), with more than 86% recommending the next Papanicolaou test sooner than recommended by guidelines. Adherence improved when the recommendation was to repeat screening in 1 year because of abnormal results (vignettes 4 and 5 shown. An estimate was considered unreliable if it was based on less than 30 responses or if its relative standard error was more than 30% (Ambulatory Health Care Data. Reliability of Estimates. http://www.cdc.gov/nchs/ahcd/ahcd _estimation_reliability.htm). Screening later than recommended was uncommon in all vignettes (Ͻ5%). These percentages had small numbers and therefore are not shown.
f Significant increase from 2006 to 2008 (P Ͻ .05). g t Tests were performed using the categories "guideline consistent" vs "not guideline consistent."
panicolaou testing sooner than recommended by guidelines, especially after normal co-testing results. A novel benefit of co-testing is the ability to extend screening intervals immediately among women who have no prior screening or whose screening history is unavailable if both test results are normal, yet the lowest adherence to guidelines was for the vignette of a woman with unknown Papanicolaou test history and negative co-test results (3.1%, all years combined). The finding of exceedingly low adherence in this scenario is troubling because reports from a large US cohort 5 demonstrate that more than 90% of women will have normal co-testing results. The highest adherence to guidelines occurred when the recommended interval was less than 3 years, suggesting that clinicians are willing to adhere to guidelines if more vigilant testing is recommended. The ability to obtain prior screening results and the use of electronic medical records or systems changes, such as office reminders or reimbursement packages, may help achieve adherence to recommended intervals.
The low response rate in 2007 (NAMCS) was a limitation of our study. However, estimates were weighted to physician population and accounted for survey nonresponse. Uncertain concordance of practitioner response to hypothetical vignette with actual practice might also be of concern. Vignettes, however, have been shown to be inexpensive and useful tools for measuring quality of care by physicians. 6 Important strengths are the inclusion of the latest NAMCS and NHAMCS data available and the consistent methodology, which make the survey a useful tool to gauge changes in clinicians' recommendations over time. Future analyses will monitor adherence to newer guidelines that recommend extending screening intervals to 5 years among women with normal co-testing results, a strategy designed to achieve a reasonable balance between benefits and harms.
ituximab is a chimeric monoclonal antibody that targets CD20 antigens on B cells. It has been approved by the US Food and Drug Administration for the treatment of B-cell non-Hodgkin lymphoma and rheumatoid arthritis that is refractory to treatment with anti-tumor necrosis factor. 1 Rituximab induces Bcell depletion and influences T-cell immunity, which could consequently predispose patients to serious infectious complications. 2 Herein we describe the reactivation of cerebral toxoplasmosis after rituximab therapy in a patient with cutaneous vasculitis associated with type I cryoglobulinemia.
Report of a Case.
A 71-year-old woman presented with cutaneous ulcerations on her legs. The patient was not taking any medications and had no history of infections. A biopsy of the skin lesions revealed small-vessel neutrophilic vasculitis, and direct immunofluorescence revealed vascular IgM deposits. Serum protein electrophoresis revealed IgM monoclonal gammopathy (480 mg/dL; to convert to milligrams per liter, multiply by 10) and type I cryoglobulinemia (cryocrit concentration, 50% 
